Want to see IRD full AI Analyst Report?

Opus Genetics (IRD) Stock Forecast & Price Target

1,304 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

IRD Analyst Ratings

Strong Buy

15 Buy

0 Hold

0 Sell

Based on 15 analysts giving stock ratings to

Opus

Genetics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

IRD Stock 12 Month Forecast

Average Price Target

$11.23

▲(264.64% Upside)

Based on 15 Wall Street analysts offering 12 month price targets for Opus Genetics in the last 3 months. The average price target is $11.23 with a high forecast of $16.00 and a low forecast of $8.00. The average price target represents a 264.64% change from the last price of $3.08.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","17":"$17","4.25":"$4.25","8.5":"$8.5","12.75":"$12.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.23076923076923,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.23</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4.25,8.5,12.75,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.71,4.655384615384615,5.600769230769231,6.546153846153846,7.491538461538461,8.436923076923076,9.382307692307691,10.327692307692306,11.273076923076921,12.218461538461536,13.163846153846151,14.109230769230766,15.054615384615385,{"y":16,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.71,4.288520710059172,4.867041420118343,5.445562130177514,6.0240828402366855,6.602603550295857,7.181124260355029,7.7596449704142,8.338165680473372,8.916686390532544,9.495207100591715,10.073727810650887,10.652248520710057,{"y":11.23076923076923,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.71,4.04,4.37,4.7,5.03,5.36,5.6899999999999995,6.02,6.35,6.68,7.01,7.34,7.67,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.07,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.23,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.01,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.32,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.33,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.69,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.14,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.12,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.18,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.71,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$16.00

Average Price Target$11.23

Lowest Price Target$8.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Francois Brisebois

LifeSci Capital

$10

Buy

224.68%

Upside

Reiterated

08/03/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Debanjana Chatterjee

JonesTrading

$10

Buy

224.68%

Upside

Reiterated

07/30/26

Analysts Offer Insights on Healthcare Companies: Quince Therapeutics (NASDAQ: QNCX) and Opus Genetics (NASDAQ: IRD)

Ritu Baral

TD Cowen

―

Buy

―

Initiated

07/29/26

Opus Genetics initiated with a Buy at TD CowenOpus Genetics initiated with a Buy at TD Cowen

Steven Seedhouse

Cantor Fitzgerald

$15

Buy

387.01%

Upside

Reiterated

07/09/26

Cantor Fitzgerald Reaffirms Their Buy Rating on Opus Genetics (IRD)

Yun Zhong

Wedbush

$10

Buy

224.68%

Upside

Reiterated

07/09/26

Opus Genetics: Buy Rating Reiterated as Analyst Sees Pivotal OPGx-BEST1 Data as Key Catalyst; $10 Price Target Unchanged

Andreas Argyrides

Chardan Capital

$13

Buy

322.08%

Upside

Reiterated

07/06/26

Opus Genetics FDA alignment further de-risks path to market, says ChardanOpus Genetics FDA alignment further de-risks path to market, says Chardan

Thomas Shrader

BTIG

$12

Buy

289.61%

Upside

Reiterated

07/06/26

Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (NASDAQ: CRNX), Opus Genetics (NASDAQ: IRD) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Albert Lowe

Craig-Hallum

―

Buy

―

Reiterated

07/06/26

Analysts Are Bullish on These Healthcare Stocks: CVRx (CVRX), Opus Genetics (IRD)

Lisa Walter

RBC Capital

$10

Buy

224.68%

Upside

Initiated

06/23/26

Opus Genetics initiated with an Outperform at RBC CapitalOpus Genetics initiated with an Outperform at RBC Capital

Matthew Caufield

H.C. Wainwright

Buy

159.74%

Upside

Reiterated

06/17/26

Analyst Reiterates Buy on Opus Genetics, Maintains $8 Price Target on Advancing Gene Therapy Pipeline

Kostas Biliouris

Oppenheimer

$10

Buy

224.68%

Upside

Reiterated

06/17/26

Oppenheimer Sticks to Their Buy Rating for Opus Genetics (IRD)

Debjit Chattopadhyay

Guggenheim

$16

Buy

419.48%

Upside

Initiated

06/04/26

Opus Genetics initiated with a Buy at GuggenheimOpus Genetics initiated with a Buy at Guggenheim

Lili (Aurélie) Nsongo

Leerink Partners

$10

Buy

224.68%

Upside

Initiated

05/21/26

Opus Genetics initiated with an Outperform at LeerinkOpus Genetics initiated with an Outperform at Leerink

Jonathan Wolleben

Citizens JMP

$12→$11

Buy

257.14%

Upside

Reiterated

05/13/26

Opus Genetics price target lowered to $11 from $12 at CitizensOpus Genetics price target lowered to $11 from $12 at Citizens

Biren Amin

Piper Sandler

$11

Buy

257.14%

Upside

Reiterated

05/08/26

Piper Sandler Sticks to Its Buy Rating for Opus Genetics (IRD)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Francois Brisebois

LifeSci Capital

$10

Buy

224.68%

Upside

Reiterated

08/03/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Debanjana Chatterjee

JonesTrading

$10

Buy

224.68%

Upside

Reiterated

07/30/26

Analysts Offer Insights on Healthcare Companies: Quince Therapeutics (NASDAQ: QNCX) and Opus Genetics (NASDAQ: IRD)

Ritu Baral

TD Cowen

―

Buy

―

Initiated

07/29/26

Opus Genetics initiated with a Buy at TD CowenOpus Genetics initiated with a Buy at TD Cowen

Steven Seedhouse

Cantor Fitzgerald

$15

Buy

387.01%

Upside

Reiterated

07/09/26

Cantor Fitzgerald Reaffirms Their Buy Rating on Opus Genetics (IRD)

Yun Zhong

Wedbush

$10

Buy

224.68%

Upside

Reiterated

07/09/26

Opus Genetics: Buy Rating Reiterated as Analyst Sees Pivotal OPGx-BEST1 Data as Key Catalyst; $10 Price Target Unchanged

Andreas Argyrides

Chardan Capital

$13

Buy

322.08%

Upside

Reiterated

07/06/26

Opus Genetics FDA alignment further de-risks path to market, says ChardanOpus Genetics FDA alignment further de-risks path to market, says Chardan

Thomas Shrader

BTIG

$12

Buy

289.61%

Upside

Reiterated

07/06/26

Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (NASDAQ: CRNX), Opus Genetics (NASDAQ: IRD) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Albert Lowe

Craig-Hallum

―

Buy

―

Reiterated

07/06/26

Analysts Are Bullish on These Healthcare Stocks: CVRx (CVRX), Opus Genetics (IRD)

Lisa Walter

RBC Capital

$10

Buy

224.68%

Upside

Initiated

06/23/26

Opus Genetics initiated with an Outperform at RBC CapitalOpus Genetics initiated with an Outperform at RBC Capital

Matthew Caufield

H.C. Wainwright

Buy

159.74%

Upside

Reiterated

06/17/26

Analyst Reiterates Buy on Opus Genetics, Maintains $8 Price Target on Advancing Gene Therapy Pipeline

Kostas Biliouris

Oppenheimer

$10

Buy

224.68%

Upside

Reiterated

06/17/26

Oppenheimer Sticks to Their Buy Rating for Opus Genetics (IRD)

Debjit Chattopadhyay

Guggenheim

$16

Buy

419.48%

Upside

Initiated

06/04/26

Opus Genetics initiated with a Buy at GuggenheimOpus Genetics initiated with a Buy at Guggenheim

Lili (Aurélie) Nsongo

Leerink Partners

$10

Buy

224.68%

Upside

Initiated

05/21/26

Opus Genetics initiated with an Outperform at LeerinkOpus Genetics initiated with an Outperform at Leerink

Jonathan Wolleben

Citizens JMP

$12→$11

Buy

257.14%

Upside

Reiterated

05/13/26

Opus Genetics price target lowered to $11 from $12 at CitizensOpus Genetics price target lowered to $11 from $12 at Citizens

Biren Amin

Piper Sandler

$11

Buy

257.14%

Upside

Reiterated

05/08/26

Piper Sandler Sticks to Its Buy Rating for Opus Genetics (IRD)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

ZURAZura Bio

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Opus Genetics

3 Months

Albert LoweCraig-Hallum

Success Rate

7/11 ratings generated profit

Average Return

+27.25%

Copying Albert Lowe's trades and holding each position for 3 Months would result in 63.64% of your transactions generating a profit, with an average return of +27.25% per trade.

1 Year

Debanjana ChatterjeeJonesTrading

Success Rate

12/16 ratings generated profit

Average Return

+126.87%

Copying Debanjana Chatterjee's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +126.87% per trade.

2 Years

Debanjana ChatterjeeJonesTrading

Success Rate

12/16 ratings generated profit

Average Return

+143.76%

Copying Debanjana Chatterjee's trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +143.76% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IRD Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IRD has received 23 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. IRD average Analyst price target in the past 3 months is 11.23.

Each month's total comprises the sum of three months' worth of ratings.

IRD Financial Forecast

IRD Earnings Forecast

Next quarter’s earnings estimate for IRD is -$0.16 with a range of -$0.27 to -$0.09. The previous quarter’s EPS was -$0.75. IRD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 40.24% of the time in the same period. In the last calendar year IRD has Performed in-line its overall industry.

IRD Sales Forecast

Next quarter’s sales forecast for IRD is $2.63M with a range of $0.00 to $6.00M. The previous quarter’s sales results were $2.16M. IRD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 44.19% of the time in the same period. In the last calendar year IRD has Performed in-line its overall industry.

IRD Stock Forecast FAQ

What is IRD’s average 12-month price target, according to analysts?

Based on analyst ratings, Opus Genetics, Inc.’s 12-month average price target is 11.23.

What is IRD’s upside potential, based on the analysts’ average price target?

Opus Genetics, Inc. has 264.64% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is IRD a Buy, Sell or Hold?

Opus Genetics, Inc. has a consensus rating of Strong Buy which is based on 15 buy ratings, 0 hold ratings and 0 sell ratings.

What is Opus Genetics, Inc.’s price target?

The average price target for Opus Genetics, Inc. is 11.23. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $16.00 ,the lowest forecast is $8.00. The average price target represents 264.64% Increase from the current price of $3.08.

What do analysts say about Opus Genetics, Inc.?

Opus Genetics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of IRD?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Opus Genetics (IRD) Stock Forecast & Price Target

IRD Analyst Ratings

IRD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Opus Genetics

IRD Analyst Recommendation Trends

IRD Financial Forecast

IRD Earnings Forecast

IRD Sales Forecast

IRD Stock Forecast FAQ

Detailed List of Analyst Forecasts